For example, LS patients with PSM2 mutations [64] develop malignancies later than other patients, while patients with MSH6 mutations have CRC and endometrial carcinoma later in life compared with MLHI or MSH2 mutation carriers [47]. This evidence concerns the gene MSH2 and colorectal carcinoma.